Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
SYDNEY, AUSTRALIA--(Marketwired - Mar 14, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces that the second cohort comprising six patients has now been fully recruited for its TACTI-mel (Two ACTive …